- Home
- EVC vs ACIU Comparison
EVC vs ACIU Comparison
Compare EVC & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVC
- ACIU
- Stock Information
- Founded
- EVC 1996
- ACIU 2003
- Country
- EVC United States
- ACIU Switzerland
- Employees
- EVC N/A
- ACIU N/A
- Industry
- EVC Broadcasting
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- EVC Industrials
- ACIU Health Care
- Exchange
- EVC Nasdaq
- ACIU Nasdaq
- Market Cap
- EVC 188.3M
- ACIU 189.1M
- IPO Year
- EVC 2000
- ACIU 2016
- Fundamental
- Price
- EVC $2.35
- ACIU $2.07
- Analyst Decision
- EVC
- ACIU Strong Buy
- Analyst Count
- EVC 0
- ACIU 1
- Target Price
- EVC N/A
- ACIU $12.00
- AVG Volume (30 Days)
- EVC 249.5K
- ACIU 125.1K
- Earning Date
- EVC 08-07-2025
- ACIU 08-05-2025
- Dividend Yield
- EVC 8.53%
- ACIU N/A
- EPS Growth
- EVC N/A
- ACIU N/A
- EPS
- EVC N/A
- ACIU N/A
- Revenue
- EVC $378,623,000.00
- ACIU $32,014,254.00
- Revenue This Year
- EVC $64.06
- ACIU N/A
- Revenue Next Year
- EVC N/A
- ACIU $533.21
- P/E Ratio
- EVC N/A
- ACIU N/A
- Revenue Growth
- EVC 23.10
- ACIU 91.20
- 52 Week Low
- EVC $1.58
- ACIU $1.43
- 52 Week High
- EVC $2.73
- ACIU $4.26
- Technical
- Relative Strength Index (RSI)
- EVC 49.68
- ACIU 55.57
- Support Level
- EVC $2.19
- ACIU $2.00
- Resistance Level
- EVC $2.60
- ACIU $2.15
- Average True Range (ATR)
- EVC 0.09
- ACIU 0.13
- MACD
- EVC -0.02
- ACIU -0.01
- Stochastic Oscillator
- EVC 16.67
- ACIU 80.92
About EVC Entravision Communications Corporation
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the Media segment. Geographically, the company generates the majority of its revenue from the United States.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.